ALK and non-small cell lung carcinoma: TP53 mutations are present in almost half of NSCLC patients and the incidence of TP53 mutations is higher in lung squamous cell carcinomas than that in lung adenocarcinomas, with mutation rates between 20% and 40% in the latter.16, 17, 18 In line with prior studies, we found that TP53 mutations occurred in 23.4% of ALK‐rearranged NSCLC patients in our case series.